Proprotein Convertase 9
High LDL elevates CV risk in older patients; primary prevention may be appropriate
High LDL in older patients may confer increased risk for atherosclerotic CVD and MI, and therefore this population may benefit from targeted LDL-lowering therapies, according to two studies published in The Lancet.
PCSK9 inhibitors lower VTE risk in patients with elevated Lp(a)
Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had elevated lipoprotein(a), according to findings presented at the virtual American College of Cardiology Scientific Session.
PCSK9 variants not linked to sepsis risk
New data published in JAMA Network Open show that PCSK9 genetic variants were not associated with the risk for sepsis or sepsis outcomes in patients hospitalized with infection.
Evolocumab shows benefit for high-risk ACS: EVOPACS
PARIS — In the first randomized trial designed to assess a PCSK9 inhibitor in patients with high-risk ACS, the addition of evolocumab to statin therapy was well tolerated and substantially reduced LDL levels, with a majority of patients within currently recommended target levels following treatment.